Advanced Oncotherapy PLC (GB:AVO)

Advanced Oncotherapy (AVO) Income Statement


Advanced Oncotherapy Income Statement

Last quarter (Q ), Advanced Oncotherapy's total revenue was £―, a decrease of ― from the same quarter last year. In Q, Advanced Oncotherapy's net income was £―. See Advanced Oncotherapy’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
---£ 0.00£ 0.00£ 0.00
Cost of Revenue
---£ 0.00£ 1.91M£ 0.00
Gross Profit
---£ 0.00£ -1.91M£ 0.00
Operating Expense
-£ 23.74M£ 20.27M£ 20.66M£ 19.94M£ 14.49M
Operating Income
-£ -23.74M£ -20.27M£ -20.66M£ -21.85M£ -14.49M
Net Non Operating Interest Income Expense
-£ 5.76M£ 5.03M£ -1.22M£ -66.69K£ -1.99M
Other Income Expense
Pretax Income
-£ -29.49M£ -25.30M£ -21.88M£ -21.91M£ -16.49M
Tax Provision
---£ -1.08M£ -759.41K£ -2.83M
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-£ -29.49M£ -25.30M£ -20.79M£ -21.15M£ -13.66M
Basic EPS
-£ -0.08£ -0.09£ -0.10£ -0.14£ -0.18
Diluted EPS
-£ -0.08£ -0.09£ -0.10£ -0.14£ -0.18
Basic Average Shares
-£ 382.48M£ 288.98M£ 211.48M£ 150.54M£ 77.83M
Diluted Average Shares
-£ 382.48M£ 288.98M£ 211.48M£ 150.54M£ 77.83M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
-£ -23.74M£ -20.27M£ 20.66M£ 21.85M£ 14.49M
Net Income From Continuing And Discontinued Operation
-£ -29.49M£ -25.30M£ -20.79M£ -21.15M£ -13.66M
Normalized Income
-£ -23.89M£ -20.49M£ -20.79M£ -21.15M£ -13.66M
Interest Expense
---£ 1.23M£ 80.19K£ 1.27M
-£ -24.43M£ -21.13M£ -20.64M£ -21.83M£ -15.21M
-£ -24.43M£ -21.13M£ -18.62M£ -21.42M£ -14.85M
Currency in GBP

Advanced Oncotherapy Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis